SNY - Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst | Benzinga
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the complement C1s protein.
The analyst notes that the first-generation complement inhibitors validate complement as a viable drug target but leave the door open for improvements.
With DNTH103 advancing in multiple Phase 2 studies and preliminary Phase 1 data demonstrating a ...